Oral SERDs Explained: The New Hormone Therapy Option After Endocrine Resistance in HR+ Breast Cancer 

n

Hormone receptor-positive, HER2-negative breast cancer is still largely driven by estrogen signaling, so endocrine therapy remains the backbone in both early and metastatic settings. 

The big change right now is that doctors are moving from reactive treatment changes after scans show progression to a more proactive approach that uses targeted therapy earlier and increasingly relies on molecular signals, such as ESR1 mutations, to guide next steps. 

One of the most important additions in this shift is the rise of oral selective estrogen receptor degraders, also called oral SERDs.

What is endocrine resistance, and why does it happens

Endocrine resistance means the cancer is no longer responding well to hormone-blocking treatment such as aromatase inhibitors or other endocrine options. 

A common biological reason is that the tumor develops changes that keep estrogen receptor signaling active even when estrogen is suppressed.

A key example is an acquired ESR1 mutation, which can emerge during endocrine therapy and become a driver of resistance. 

That is why ESR1 mutation testing has become more important for selecting the next endocrine strategy. 

What are oral SERDs, and how are they different

Traditional endocrine drugs often work by lowering estrogen levels or by blocking estrogen receptors. SERDs go one step further: they target the estrogen receptor for degradation, helping shut down signaling more completely.

Oral SERDs matter because they are easier to take than injectable options and are being developed to be more potent, especially for tumors with ESR1-driven resistance. 

Where oral SERDs fit after CDK4/6 inhibitors

CDK4/6 inhibitors plus endocrine therapy became the standard first-line approach for many patients with HR positive, HER2-negative metastatic breast cancer.

When the disease progresses on that combination, the next step is increasingly guided by tumor biology, especially ESR1 status.

Example: Elacestrant for ESR1 mutated disease

Elacestrant, an oral SERD, is FDA approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on at least one line of endocrine therapy.

This approval reflects the idea that if an ESR1 mutation is present, switching to an oral SERD can be a more targeted move than simply rotating among older endocrine options.

Example: Imlunestrant approved in 2025 for ESR1 mutated disease

Imlunestrant is also FDA approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression following at least one line of endocrine therapy. 

The next shift: acting before scans show progression

A newer concept is early switching based on blood-based monitoring rather than waiting for radiographic progression.

SERENA-6 in simple terms

SERENA-6 is a phase 3 study in which patients on first-line aromatase inhibitor plus CDK4/6 inhibitor receive regular ctDNA monitoring. If an ESR1 mutation is detected in blood, the endocrine drug can be switched to an investigational oral SERD while continuing the same CDK4/6 inhibitor, aiming to extend disease control. 

Publicly reported results showed a meaningful improvement in progression-free survival with this early switch concept compared with continuing on the aromatase inhibitor. 

What this means for patients: the care model is moving toward earlier detection of resistance and earlier adjustment, rather than waiting for the cancer to declare resistance on scans.

Why this matters for quality of life

For many patients, the goal is longer control with fewer disruptions to daily life. Oral endocrine options can reduce clinic time and keep treatment simpler, but every drug still has side effects and tradeoffs.

The practical direction from expert discussions is:

• Match therapy to biology, especially ESR1, when resistance is suspected
• Use targeted add-ons thoughtfully
• Manage side effects early so patients can stay on effective therapy longer 

FAQ

When should ESR1 be tested?

Often at recurrence or progression, and increasingly in strategies that consider earlier blood-based detection of emerging resistance.

If I have an ESR1 mutation, does that change treatment?

Yes. ESR1-mutated disease is a key setting in which an oral SERD may be a better-matched endocrine option than older approaches. 

Is it an oral SERD chemotherapy?

No. Oral SERDs are endocrine-targeted therapy, not chemotherapy.

Key takeaway

Oral SERDs are becoming a major option after endocrine resistance in HR positive, HER2-negative breast cancer, especially when ESR1 mutations are involved. 

The field is also moving toward proactive management using blood-based molecular monitoring to switch endocrine therapy earlier and potentially extend the benefit of first-line regimens. 

References

1. Advancing care in HR+ breast cancer: integrating CDK4/6 inhibition, SERDs, and early intervention strategies. OncLive Peer Exchange. December 10, 2025. Accessed December 22, 2025.
2. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 5.2025. National Comprehensive Cancer Network. Accessed December 22, 2025.
3. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. U.S. Food and Drug Administration. January 2023.
4. FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. U.S. Food and Drug Administration. September 2025.
5. SERENA-6 trial information. ClinicalTrials.gov Identifier: NCT04964934.